Epoch/Specialty launch leukaemia test:
This article was originally published in Clinica
The first product to emerge from the partnership between molecular diagnostics company Epoch Biosciences (Bothell, Washington) and reference laboratory Specialty Laboratories (see Clinica No 910, p 13) is now commercially available. The BCR/ABL UltraQuant by MGB PCR test incorporates Epoch's proprietary Minor Groove Binder technology, and is used to identify residual leukaemia cells after radiation treatment and chemotherapy, and for monitoring drug therapy over time. The companies claim that the test is up to 3,000 times as sensitive as traditional bcr/abl PCR tests, which improves the physician's ability to detect early signs of and relapse.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.